Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy The collaboration is focused on advancing clinical development and commercialization of the oncolytic virus-based cell therapy
March 11, 2021 07:00 ET | Source: Orgenesis Inc. Orgenesis Inc.
GERMANTOWN, Md., March 11, 2021 (GLOBE NEWSWIRE)
. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announces that it has entered the planned second phase of a collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, Spain. The collaboration is focused on an exclusive license agreement to further develop and commercialize the hospital’s proprietary Celyvir therapy for the treatment of solid tumors.
Search jobs 10-Mar-2021 Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea
Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea
. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), Dong-a University Hospital in South Korea, and Cure Therapeutics, Inc. (“Cure Therapeutics”), a developer of immuno-oncology and cell and gene therapies to target cancer and infectious diseases, today announce the signing of a collaboration agreement. The teams will align to utilise Orgenesis Mobile Proc
Share:
Revenue increases 96% to $7.7 million for 2020
Projects to more than double in revenue for 2021 based on current contracts already in hand
Orgenesis to host conference call today at 8:30AM ET
GERMANTOWN, Md., March 09, 2021 (GLOBE NEWSWIRE)
. (NASDAQ:ORGS) ( Orgenesis or the Company ), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today reported financial results for the year ended December 31, 2020 and provided a business update.
Vered Caplan, CEO of Orgenesis, commented, Just over a year ago, we completed the sale of one of our business divisions, which provided centralized manufacturing subcontracting services to cell and gene biotech companies. This activity was incorporated in the Masthercell subsidiary, a contract development manufacturing organization (CDMO). The CDMO was sold for $315 million, generating approximately $127 million of proceeds to Orgenesis. We determined it was the right time to sell Masth
Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Orgenesis signs JV with Korean CGT developer US headquartered company, Orgenesis, and South Korea-based, Cure Therapeutics, have signed a JV deal to advance the development, regulatory approval, and commercialization of point of care production for both companies’ cell and gene therapies and immunotherapies.
“The joint venture and partnership with Orgenesis will provide a significant international route to market for our immunotherapies targeting cancers and infectious diseases,” said David Kim, CEO of Cure Therapeutics.
Under the deal, the parties will collaborate in developing and commercializing Cure Therapeutics’ pipeline on a global basis, as well as developing, commercializing and supplying Orgenesis’ therapeutic pipeline in South Korea and Japan.